PDCD1 and metastatic melanoma: In conclusion, this study construct a nomogram based on the baseline levels of thyroid antibodies, thyroid status, serum LDH, and M stage before anti–PD-1, showing that the factors are strong predictive markers for response and prognosis to anti–PD-1 treatment in metastatic melanoma.